These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35873586)

  • 1. Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage.
    Jiang W; Zhang Z; Zhu Y; Chen B; Gu C; Liu Z; Zhang X; Xiong H; Zhang Y; Zheng B; Wang R; Jiao S; Wang A; Zhang T; Zhang J; Wang S; Zhang B; Li G; Gui X
    Front Pharmacol; 2022; 13():926750. PubMed ID: 35873586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination.
    Chen X; Chen Z; Azman AS; Sun R; Lu W; Zheng N; Zhou J; Wu Q; Deng X; Zhao Z; Chen X; Ge S; Yang J; Leung DT; Yu H
    medRxiv; 2021 May; ():. PubMed ID: 33972950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent neutralizing RBD-specific antibody cocktail against SARS-CoV-2 and its mutant.
    Jia L; Liu YP; Tian LF; Xiong C; Xu X; Qu H; Xiong W; Zhou D; Wang F; Liu Z; Yan XX; Xu W; Tang L
    MedComm (2020); 2021 Sep; 2(3):442-452. PubMed ID: 34541573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients.
    Carreño JM; Alshammary H; Singh G; Raskin A; Amanat F; Amoako A; Gonzalez-Reiche AS; van de Guchte A; Study Group P; Srivastava K; Sordillo EM; Sather DN; van Bakel H; Krammer F; Simon V
    EBioMedicine; 2021 Nov; 73():103626. PubMed ID: 34688034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity.
    Liu H; Wei P; Kappler JW; Marrack P; Zhang G
    Front Immunol; 2022; 13():825256. PubMed ID: 35154144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera.
    Hu J; Wei XY; Xiang J; Peng P; Xu FL; Wu K; Luo FY; Jin AS; Fang L; Liu BZ; Wang K; Tang N; Huang AL
    Genes Dis; 2022 Sep; 9(5):1290-1300. PubMed ID: 34877393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
    Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
    Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape.
    Starr TN; Czudnochowski N; Zatta F; Park YJ; Liu Z; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Tucker H; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Cameroni E; Croll TI; Nix JC; Havenar-Daughton C; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Whelan SPJ; Virgin HW; Veesler D; Corti D; Bloom JD; Snell G
    bioRxiv; 2021 Apr; ():. PubMed ID: 33851154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants.
    Qu Y; Zhang X; Wang M; Sun L; Jiang Y; Li C; Wu W; Chen Z; Yin Q; Jiang X; Liu Y; Li C; Li J; Ying T; Li D; Zhan F; Wang Y; Guan W; Wang S; Liang M
    Virol Sin; 2021 Oct; 36(5):934-947. PubMed ID: 34224110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment.
    Li D; Sempowski GD; Saunders KO; Acharya P; Haynes BF
    Annu Rev Med; 2022 Jan; 73():1-16. PubMed ID: 34428080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential for a Plant-Made SARS-CoV-2 Neutralizing Monoclonal Antibody as a Synergetic Cocktail Component.
    Jugler C; Sun H; Grill F; Kibler K; Esqueda A; Lai H; Li Y; Lake D; Chen Q
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2.
    Sun C; Chi H; Yuan F; Li J; Yang J; Zheng A; Wang F; Sun L; Zhang Y; Hu P; Jiao L; Deng Y; Xie L
    Sci China Life Sci; 2023 Jan; 66(1):165-179. PubMed ID: 36184693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
    Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
    Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo.
    Zhang Z; Zeng E; Zhang L; Wang W; Jin Y; Sun J; Huang S; Yin W; Dai J; Zhuang Z; Chen Z; Sun J; Zhu A; Li F; Cao W; Li X; Shi Y; Gan M; Zhang S; Wei P; Huang J; Zhong N; Zhong G; Zhao J; Wang Y; Shao W; Zhao J
    Cell Discov; 2021 Aug; 7(1):65. PubMed ID: 34385423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.